Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Thumbnail
View/Open
Published version (775.5Kb)
Date
2016-09
ICR Author
De Bono, Johann
Author
Smith, M
De Bono, J
Sternberg, C
Le Moulec, S
Oudard, S
De Giorgi, U
Krainer, M
Bergman, A
Hoelzer, W
De Wit, R
Bögemann, M
Saad, F
Cruciani, G
Thiery-Vuillemin, A
Feyerabend, S
Miller, K
Houédé, N
Hussain, S
Lam, E
Polikoff, J
Stenzl, A
Mainwaring, P
Ramies, D
Hessel, C
Weitzman, A
Fizazi, K
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Purpose Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). This blinded phase III trial compared cabozantinib with prednisone in patients with mCRPC.Patients and methods Men with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide were randomly assigned at a two-to-one ratio to cabozantinib 60 mg once per day or prednisone 5 mg twice per day. The primary end point was overall survival (OS). Bone scan response (BSR) at week 12 as assessed by independent review committee was the secondary end point; radiographic progression-free survival (rPFS) and effects on circulating tumor cells (CTCs), bone biomarkers, serum prostate-specific antigen (PSA), and symptomatic skeletal events (SSEs) were exploratory assessments.Results A total of 1,028 patients were randomly assigned to cabozantinib (n = 682) or prednisone (n = 346). Median OS was 11.0 months with cabozantinib and 9.8 months with prednisone (hazard ratio, 0.90; 95% CI, 0.76 to 1.06; stratified log-rank P = .213). BSR at week 12 favored cabozantinib (42% v 3%; stratified Cochran-Mantel-Haenszel P < .001). rPFS was improved in the cabozantinib group (median, 5.6 v 2.8 months; hazard ratio, 0.48; 95% CI, 0.40 to 0.57; stratified log-rank P < .001). Cabozantinib was associated with improvements in CTC conversion, bone biomarkers, and post-random assignment incidence of SSEs but not PSA outcomes. Grade 3 to 4 adverse events and discontinuations because of adverse events were higher with cabozantinib than with prednisone (71% v 56% and 33% v 12%, respectively).Conclusion Cabozantinib did not significantly improve OS compared with prednisone in heavily treated patients with mCRPC and progressive disease after docetaxel and abiraterone and/or enzalutamide. Cabozantinib had some activity in improving BSR, rPFS, SSEs, CTC conversions, and bone biomarkers but not PSA outcomes.
URI
https://repository.icr.ac.uk/handle/internal/457
DOI
https://doi.org/10.1200/jco.2015.65.5597
Collections
  • Clinical Studies
Subject
Humans
Neoplasm Metastasis
Anilides
Pyridines
Prednisone
Antineoplastic Agents
Protein Kinase Inhibitors
Disease-Free Survival
Survival Rate
Double-Blind Method
Adult
Aged
Aged, 80 and over
Middle Aged
Male
Neoplastic Cells, Circulating
Prostatic Neoplasms, Castration-Resistant
Biomarkers, Tumor
Research team
Prostate Cancer Targeted Therapy Group
Language
eng
License start date
2016-09
Citation
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 34 (25), pp. 3005 - 3013

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.